Your browser is no longer supported. Please, upgrade your browser.
Settings
PRAN Prana Biotechnology Ltd daily Stock Chart
PRAN [NASD]
Prana Biotechnology Ltd
Index- P/E- EPS (ttm)-0.66 Insider Own- Shs Outstand536.97M Perf Week-
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float1.34M Perf Month-
Income- PEG- EPS next Q- Inst Own3.61% Short Float10.11% Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y-
Book/sh1.32 P/B- EPS next Y- ROA- Target Price4.00 Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range- - - Perf YTD-
Dividend- P/FCF- EPS past 5Y- ROI- 52W High- Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low- ATR-
Employees14 Current Ratio- Sales Q/Q68.70% Oper. Margin- RSI (14)- Volatility- -
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume- Prev Close-
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume- Price-
Recom- SMA20- SMA50- SMA200- Volume0 Change-
Apr-10-19 09:02PM  Alterity Therapeutics Launches to Asian Investors Business Wire
Jan-31-19 09:01AM  Prana Receives First Orphan Drug Designation from the FDA for the Treatment of Multiple System Atrophy Business Wire
Jan-04-19 06:50AM  Today's Research Reports on Trending Tickers: Prana Biotechnology and Gilead Sciences ACCESSWIRE
Jan-02-19 12:48PM  Why Prana Biotechnology Stock Is Skyrocketing Today InvestorPlace
10:25AM  Prana Biotech Surges on Promised $31.4 Million Investment TheStreet.com
09:25AM  Watch These Top Trending Stocks On Jan. 2, 2019 ACCESSWIRE
07:00AM  Life Biosciences LLC leads strategic investment of up to A$44.5 million (US$31.4 million) in Prana PR Newswire
Dec-11-18 07:16PM  Is Prana Biotechnology Limiteds (ASX:PBT) CEO Pay Justified? Simply Wall St.
Oct-12-18 12:35AM  How Financially Strong Is Prana Biotechnology Limited (ASX:PBT)? Simply Wall St.
Oct-04-18 11:47PM  Prana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential Treatment for MSA Business Wire
Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson's disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer's disease. It also completed the IMAGINE Phase II biomarker imaging trial in Alzheimer's disease; and a open label IMAGINE Extension study and the Reach2HD Phase IIa trial in Huntington disease. The company was founded in 1997 and is based in Melbourne, Australia.